Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Operating Expenses (2016 - 2025)

Fennec Pharmaceuticals' Other Operating Expenses history spans 8 years, with the latest figure at $7.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses rose 70.6% year-over-year to $7.9 million, compared with a TTM value of $22.4 million through Dec 2025, up 3.57%, and an annual FY2025 reading of $22.4 million, up 3.56% over the prior year.
  • Other Operating Expenses for Q4 2025 was $7.9 million at Fennec Pharmaceuticals, up from $5.9 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $7.9 million in Q4 2025, with the low at -$10.0 million in Q2 2022.
  • Average Other Operating Expenses over 4 years is $3.6 million, with a median of $4.6 million recorded in 2023.
  • Year-over-year, Other Operating Expenses skyrocketed 124.84% in 2023 and then tumbled 42.35% in 2025.
  • Tracing FENC's Other Operating Expenses over 4 years: stood at $2.8 million in 2022, then surged by 63.48% to $4.6 million in 2023, then grew by 1.32% to $4.6 million in 2024, then surged by 70.6% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Other Operating Expenses are $7.9 million (Q4 2025), $5.9 million (Q3 2025), and $5.3 million (Q2 2025).